The 2025 EU Drug Report uncovers a rapidly evolving drug landscape, fuelled by synthetic substances, tech innovation, and global instability. With rising health and security threats, the report places urgent emphasis on real-time data, early warning systems, and bold cross-sector collaboration.
As the EU prepares its 2026–2030 Drug Strategy, we call for a balanced, health-oriented approach that prioritises harm reduction and rights protections instead of punishment.
The upcoming strategy Drug Strategy offers an opportunity to remediate the lack of adequate support for harm reduction services and promote health outcomes and rights.
C-EHRN's civil society monitoring identifies necessary but unequal progress on treatment and access to services, decrying enduring challenges related to funding, legislation, stigma and political will.
Join C-EHRN’s webinar on 9 May to explore Europe’s emerging nitazene threat, addressing trends, health risks, policy responses, and harm reduction strategies.
Despite repressive attempts by Hungary's ruling party to dismantle it, Budapest's progressive, rights-based city drug strategy endures in the absence of a national drug framework.
TNI, GDPO and WOLA engage with six European countries to discuss trends towards reform in cannabis policy, offering innovative solutions for legal tensions, coordination and policy development.
The webinars aim to enhance the knowledge and skills of community-based and community-led organisations, helping them apply good practice models, tools, and methods to scale up integrated screening, testing, treatment and care for communicable diseases across Europe.
